Verici Logo

Company announcements

  • Register for news alerts from Verici Dx

  • This field is for validation purposes and should be left unchanged.

Company announcements

 

Notice of Change of AGM Venue

May 5, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces a change in venue of its Annual General Meeting (‘AGM’), which will now take place at Harwood Capital, 6 Stratton Street, Mayfair, W1J 8LD on 19 May 2021 at 12.00pm.   As previously announced, the Company is providing a facility […]
Keep Reading

Lease signed for laboratory as part of CLIA approval acceleration strategy

April 29, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has signed the lease for the premises intended to be the CLIA1-certified laboratory, situated at the Innovation Park2 in Franklin, Tennessee, US, which is within the Palmetto region for CMS Medicare governance. Palmetto GBA, LLC is one of the […]
Keep Reading

Material Transfer Agreement secured to assess CTOT-19 samples using Clarava™ and Tuteva™

April 14, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has entered into a Material Transfer Agreement (“MTA”) with the Icahn School of Medicine at Mount Sinai and Principal Investigator Dr. Peter Heeger, to allow access to samples from the CTOT-19 (Clinical Trials in Organ Transplant1) trial in an […]
Keep Reading

Final Results for the period ended 31 December 2020

April 14, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its inaugural audited results for the period ended 31 December 2020.   Strategic and Operational highlights Verici Dx was successfully admitted to AIM in November raising gross proceeds of c.$18.8m (£14.5m) The fundraising was significantly oversubscribed by institutional and other […]
Keep Reading

First clinical trial sites initiated in US

March 2, 2021
Three leading US centres first to collaborate with Verici in clinical validation trial for lead products Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has partnered with Lorenzo Gallon, MD, at Northwestern University Feinberg School of Medicine; Milagros Samaniego, MD, at Henry Ford Health System and […]
Keep Reading

Additional patent licence with Mount Sinai

January 11, 2021
Worldwide exclusive licence to liquid biopsy IP for predicting risk of fibrosis and chronic damage rejection Strengthens patent portfolio covering the entire kidney transplant diagnostic pathway   Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has expanded the scope of its licence agreement with the Icahn […]
Keep Reading

Appointment of Senior Director of Clinical Trial Operations Preparatory phase for validation trials complete

December 23, 2020
23 December 2020 Verici Dx plc (“Verici Dx” or the “Company”) Appointment of Senior Director of Clinical Trial Operations Preparatory phase for validation trials complete Site initiation of transplant centres on track for January 2021 Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has appointed Angela […]
Keep Reading

TR-1: Standard form for notification of major holdings

November 13, 2020
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: VERICI DX 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an […]
Keep Reading

TR-1: Standard form for notification of major holdings

November 13, 2020
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: VERICI DX 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an […]
Keep Reading

TR-1: Standard form for notification of major holdings

November 5, 2020
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:             Verici DX Plc 1b. Please indicate if the issuer is a non-UK issuer (please mark […]
Keep Reading
1 2
© 2021 VericiDx

 Privacy Policy | Clinical Trials Privacy Policy | Cookie Policy
crossmenu